These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 17497046

  • 1. Eprosartan in secondary prevention of stroke: the economic evidence.
    Wessels F.
    Cardiovasc J Afr; 2007; 18(2):95-6. PubMed ID: 17497046
    [No Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B.
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [Abstract] [Full Text] [Related]

  • 3. [Adjustment of antihypertensive therapy to a generic eprosartan preparation. Results of a non-interventional study].
    Nüdling S, Kahner-Gröne S, Köneke D, Marggraf K, Palissa H.
    MMW Fortschr Med; 2010 Oct 14; 152 Suppl 3():96-101. PubMed ID: 21595153
    [No Abstract] [Full Text] [Related]

  • 4. Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
    Cardiovasc J S Afr; 2005 Oct 14; 16(1):56. PubMed ID: 15778775
    [No Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D, Hill MD.
    Expert Rev Cardiovasc Ther; 2009 May 14; 7(5):459-64. PubMed ID: 19419253
    [Abstract] [Full Text] [Related]

  • 6. [Stroke prevention. Is there an added value to RAS inhibition?].
    MMW Fortschr Med; 2000 Feb 10; 142(6):62-3. PubMed ID: 10832360
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H.
    Curr Med Res Opin; 2007 Nov 10; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [Abstract] [Full Text] [Related]

  • 11. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov 10; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment.
    Labiós M, Martínez M, Gabriel F, Guiral V, Dasi F, Beltrán B, Muñoz A.
    J Renin Angiotensin Aldosterone Syst; 2009 Mar 10; 10(1):24-30. PubMed ID: 19286755
    [Abstract] [Full Text] [Related]

  • 20. [Antihypertensive drug. Dual action lowers blood pressure more effectively].
    MMW Fortschr Med; 2001 May 03; 143(18):49. PubMed ID: 11387709
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.